Protagonist Therapeutics (PTGX) Stock Rating Upgraded by Zacks Investment Research

Protagonist Therapeutics (NASDAQ:PTGX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States. “

Shares of NASDAQ PTGX opened at $6.77 on Wednesday. The stock has a market cap of $154.07 million, a PE ratio of -3.24 and a beta of 3.30. Protagonist Therapeutics has a 1 year low of $5.49 and a 1 year high of $23.97.



Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Tuesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). The business had revenue of $6.12 million for the quarter, compared to analyst estimates of $6.35 million. Protagonist Therapeutics had a negative net margin of 70.54% and a negative return on equity of 24.08%. Sell-side analysts anticipate that Protagonist Therapeutics will post -1.58 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. boosted its holdings in Protagonist Therapeutics by 3.7% during the second quarter. American Century Companies Inc. now owns 148,076 shares of the company’s stock worth $995,000 after purchasing an additional 5,242 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Protagonist Therapeutics by 26.6% during the second quarter. Bank of New York Mellon Corp now owns 63,269 shares of the company’s stock worth $426,000 after purchasing an additional 13,303 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Protagonist Therapeutics by 2.6% during the third quarter. Vanguard Group Inc. now owns 530,495 shares of the company’s stock worth $5,458,000 after purchasing an additional 13,341 shares during the last quarter. FMR LLC boosted its holdings in Protagonist Therapeutics by 0.5% during the second quarter. FMR LLC now owns 3,180,583 shares of the company’s stock worth $21,374,000 after purchasing an additional 15,017 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in Protagonist Therapeutics by 6.8% during the third quarter. Acadian Asset Management LLC now owns 249,704 shares of the company’s stock worth $2,570,000 after purchasing an additional 15,874 shares during the last quarter. Institutional investors and hedge funds own 66.20% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.

Recommended Story: What are municipal bonds?

Get a free copy of the Zacks research report on Protagonist Therapeutics (PTGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply